Continuing a trend that began in 2017, this year has seen the rise of big investment deals in the biotech sector. Smaller biotechs are also cashing in as Big Pharma look to fill dwindling pipelines; according to Bloomberg data, biotech acquisitions are expected to be at the highest level for 12 years.
Analysing this data from the Biotechgate database, which tracks financial rounds in the Biotech sector revels two key trends: 1) Larger investment deals and 2) A larger proportion of Series A and Series B deals.
So, what factors have been driving larger, earlier investment in biotech firms?
Would you like to be notified about new articles, reports and other valuable content published by Venture Valuation?